HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency

Nephrology Dialysis Transplantation

Volumn 26, Issue 11, 2011, Pages 3567-3572

  Jung, Jae Woo ^a   Song, Woo Jung ^a   Kim, Yon Su ^a   Joo, Kwon Wook ^a   Lee, Kyung Wha ^b   Kim, Sae Hoon ^a,c   Park, Heung Woo ^a   Chang, Yoon Seok ^a,c   Cho, Sang Heon ^a   Min, Kyung Up ^a   Kang, Hye Ryun ^a  

^a Seoul National University   (South Korea)

^b Hallym University   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

allopurinol; chronic renal insufficiency; drug hypersensitivity; HLA; Koreans

Indexed keywords

ALLOPURINOL; HLA B ANTIGEN; HLA B58 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL DECISION MAKING; CONTROLLED STUDY; DISEASE COURSE; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; FEMALE; HLA TYPING; HUMAN; INCIDENCE; KIDNEY TRANSPLANTATION; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROTEIN FUNCTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEVERE CUTANEOUS ADVERSE REACTION; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TREATMENT PLANNING;

ADOLESCENT; ADULT; ALLOPURINOL; BIOLOGICAL MARKERS; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW-UP STUDIES; GOUT SUPPRESSANTS; HLA-B ANTIGENS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; STEVENS-JOHNSON SYNDROME; YOUNG ADULT;

EID: 80155198743     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr060     Document Type: Article

References (26)

1. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-1285
2. Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-1607
3. Mockenhaupt M, Viboud C, Dunant A et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCARstudy. J Invest Dermatol 2008; 128: 35-44
4. Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol 2002; 14: 281-286
5. Pluim HJ, van Deuren M, Wetzels JF. The allopurinol hypersensitivity syndrome. Neth J Med 1998; 52: 107-110
6. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum 1986; 29: 82-87
7. Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford) 2009; 48 (Suppl 2): Ii2-ii8
8. Tassaneeyakul W, Jantararoungtong T, Chen P et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009; 19: 704-709
9. Lonjou C, Borot N, Sekula P et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18: 99-107
10. Alfirevic A, Jorgensen AL, Williamson PR et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006; 7: 813-818
11. Hung SI, Chung WH, Liou LB et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102: 4134-4139
12. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: A clinical classification. J Invest Dermatol 1994; 102: 28S-30S
13. Lee KW, Oh DH, Lee C et al. Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population. Tissue Antigens 2005; 65: 437-447
14. Nassif A, Bensussan A, Boumsell L et al. Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114: 1209-1215
15. Chung WH, Hung SI, Hong HS et al. Medical genetics: A marker for Stevens-Johnson syndrome. Nature 2004; 428: 486
16. Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-732
17. Park WB, Choe PG, Song KH et al. Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir? Clin Infect Dis 2009; 48: 365-367
18. Chan SH, Tan T. HLA and allopurinol drug eruption. Dermatologica 1989; 179: 32-33
19. Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007; 7: 317-323
20. Kang HR, Jee YK, Kim YS, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011[Epub ahead of print]
21. Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008; 9: 1617-1622
22. Gutierrez-Macias A, Lizarralde-Palacios E, Martinez-Odriozola P et al. Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia. BMJ 2005; 331: 623-624
23. Smith JA, Marker-Hermann E, Colbert RA. Pathogenesis of ankylosing spondylitis: Current concepts. Best Pract Res Clin Rheumatol 2006; 20: 571-591
24. Becker MA, Schumacher HR Jr. Wortmann RL et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450-2461
25. Vogt B. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant 2005; 20: 431-433
26. Zhang W, Doherty M, Bardin T et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312-1324